tag:blogger.com,1999:blog-50590395687548335812024-03-15T01:58:02.957-04:00Sickle Cell BlogMarketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.comBlogger20125tag:blogger.com,1999:blog-5059039568754833581.post-49848925458225083852018-06-30T21:25:00.001-04:002018-06-30T21:25:52.733-04:00July 2018 Sickle Cell News<div class="qtdSeparateBR" id="yui_3_16_0_ym19_1_1530300050039_20813" style="background-color: white; font-family: "times new roman", "new york", times, serif; font-size: 13px;">
<br /></div>
<div class="yahoo_quoted" style="background-color: white; font-family: "times new roman", "new york", times, serif; font-size: 13px;">
<div style="font-family: HelveticaNeue, "Helvetica Neue", Helvetica, Arial, "Lucida Grande", sans-serif; font-size: 16px;">
<div class="y_msg_container">
<div id="yiv3454509027">
<div style="font-family: "times new roman", "new york", times, serif; font-size: 13px;">
<div class="yiv3454509027yahoo_quoted" id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16972">
<div id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16971">
<div id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16970" style="font-family: HelveticaNeue, "Helvetica Neue", Helvetica, Arial, "Lucida Grande", sans-serif; font-size: 16px;">
<div class="yiv3454509027y_msg_container" id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16969">
<div id="yiv3454509027">
<div id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16968">
<div class="yiv3454509027WordSection1" id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16967">
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<a href="https://www.blogger.com/blogger.g?blogID=5059039568754833581" name="_Hlk512665419" rel="nofollow" style="color: #954f72;"></a><a href="https://www.blogger.com/blogger.g?blogID=5059039568754833581" name="_Hlk484520228" rel="nofollow" style="color: #954f72;"></a><a href="https://www.blogger.com/blogger.g?blogID=5059039568754833581" name="_Hlk497199577" rel="nofollow" style="color: #954f72;"><b><span style="font-size: 14pt; line-height: 21.466665267944336px;">Sickle Cell News for July 2018– To join or leave the listserv visit </span></b></a><a href="http://scinfo.org/newsletter/" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-size: 14pt; line-height: 21.466665267944336px;">http://scinfo.org/newsletter/</span></a><u><span style="color: blue; font-size: 14pt; line-height: 21.466665267944336px;"></span></u></div>
<div id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16966">
<span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16965"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16964"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16963"><b id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16962"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16961" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">The Centers for Disease Control and Prevention (CDC) is sharing new resources on transition to help teenagers and young adults with sickle cell disease (SCD) ‘step up’ and to take ownership of their own health. </span></b></span></span></span><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16976"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16975"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16974"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16973" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">These resources aim to support and to empower young people with SCD to manage and to prioritize their health and well-being.</span></span></span></span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<ol id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16987" start="1" style="margin-bottom: 0in;" type="1">
<li id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16986"><img align="right" data-id="0916e625-6cdc-c9fa-ad68-80f0fc589fe3" height="192" hspace="12" src="blob:https://www.blogger.com/cff92f57-b325-4dcc-a12c-1e6308f52331" style="min-height: 2in; width: 3.55in;" width="341" /><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16985"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16984"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16983"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16982" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Stepping Up: A 2-Part Video Series for Teenagers & Young Adults with SCD</span></span></span></span></li>
</ol>
<div id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16981">
<span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16980"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16979"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16978"><span id="yiv3454509027yui_3_16_0_ym19_1_1530300050039_16977" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">One of the resources is a new 2-part video series focusing on health care transition among teenagers and young adults living with SCD. The videos feature Kevin and Calvanay, two young adults with SCD, who share their thoughts about transition, how it has affected them, and how they’ve overcome challenges. Watch Kevin’s (</span></span></span></span><a href="https://www.cdc.gov/ncbddd/sicklecell/materials/video.html?s_cid=ncbddd_sc_v1_ash_2018_6&#su-p1" rel="nofollow" style="color: #954f72;" target="_blank"><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">https://www.cdc.gov/ncbddd/sicklecell/materials/video.html?s_cid=ncbddd_sc_v1_ash_2018_6&#su-p1 </span></a><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">) and Calvanay’s (</span><a href="https://www.cdc.gov/ncbddd/sicklecell/materials/video.html?s_cid=ncbddd_sc_v2_ash_2018_6&#su-p2" rel="nofollow" style="color: #954f72;" target="_blank"><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">https://www.cdc.gov/ncbddd/sicklecell/materials/video.html?s_cid=ncbddd_sc_v2_ash_2018_6&#su-p2 </span></a><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">) videos. Share these videos with a teenager or a young adult living with SCD to help support his or her transition!</span></div>
<div>
<i><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></i></div>
<div>
<i><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">“I really promote self-advocacy because you need to know yourself. If you don’t know yourself, then who else does?...You have to teach others,” said Calvanay about preparing for transition.</span></i></div>
<div>
<i><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></i></div>
<ol start="2" style="margin-bottom: 0in;" type="1">
<li><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Mikeia Green’s Personal Story</span></li>
</ol>
<div>
<img align="right" data-id="ffd3486e-7a53-2034-8ef0-b857dfb85040" height="142" hspace="12" src="blob:https://www.blogger.com/41944ae4-ea85-45b7-89ca-a5bbd59d9000" style="min-height: 1.483in; width: 1.658in;" width="159" /><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">In 2012, Mikeia Green left home to attend college out of state. For most of her childhood, her mother made sure her SCD was well managed, but once she left for college it became Mikeia’s responsibility to know her body’s needs. Read how she managed her doctor’s appointments, prepared herself for emergencies, and how she prioritized her health, school, activities, and a new social life to stay healthy in college.</span></div>
<div>
<i><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></i></div>
<div>
<i><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">“I knew there were a lot of things I could do to help myself stay healthy. I didn’t want to end up in the hospital and miss class,” said Mikeia Green about her experience managing SCD in college. When Mikeia left her home in Arizona to attend college in California, it was the first time she was away from her mother…” </span></i></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Her full story will be available here: </span><a href="https://www.cdc.gov/ncbddd/sicklecell/stories.html" rel="nofollow" style="color: #954f72;" target="_blank"><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">https://www.cdc.gov/ncbddd/sicklecell/stories.html</span></a><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Help spread the word! Use the attached document to share messages and resources on websites and social media channels. Don’t forget to follow us on Twitter </span><a href="https://twitter.com/CDC_NCBDDD" rel="nofollow" style="color: #954f72;" target="_blank"><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">@CDC_NCBDDD</span></a><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> to stay-up-to-date on all of our activities! </span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">We hope you find these materials useful as you engage your community in SCD awareness. Please forward this message and its attachment to individuals in your network, so they may collaborate with you on this important public health initiative.</span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div>
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Henrico twins with sickle cell disease take on Washington </span></b><a href="https://www.wric.com/news/politics/capitol-connection/henrico-twins-with-sickle-cell-disease-take-on-washington/1271772367" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">https://www.wric.com/news/politics/capitol-connection/henrico-twins-with-sickle-cell-disease-take-on-washington/1271772367</span></b></a><b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></b></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Twin boys from the Richmond area are taking on your lawmakers to make sure kids who are in the hospital get the support they need from Washington. </span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Gabriel and Noah Cypress look like your average 9-year-olds. They love running around; Gabriel plays basketball and Noah is working on another original book. </span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">But when they were born, mom LaToya Cypress says the doctors told them something shocking - the twins had sickle cell disease. </span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">“The number of hospitalizations they’ve had, we stopped counting a long time ago. It’s almost as common, or as normal, as going to the grocery store,” she explained.</span></div>
<div>
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></b></div>
<div>
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Sickle Cell Patients Suffer As Disparities In Care And Research Persist </span></b></div>
<div>
<a href="http://wnpr.org/post/sickle-cell-patients-suffer-disparities-care-and-research-persist" rel="nofollow" style="color: #954f72;" target="_blank"><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">http://wnpr.org/post/sickle-cell-patients-suffer-disparities-care-and-research-persist</span></a><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">The disease affects some 100,000 Americans, about one in 365 African Americans and one out of 16,300 Hispanics; and in lesser numbers, people with Middle Eastern, Indian, Caribbean and Mediterranean ancestries. An estimated 2,000 people in Connecticut have SCD.</span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">But the disease—discovered over 100 years ago—receives little research, funding and attention.</span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">• Just two medications have been developed to treat the disease: hydroxyurea, approved in 1998; and Endari, approved in 2017.</span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">• There is no national data registry for tracking the disease.</span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">• Only four of the state’s 27 acute care hospitals have sickle cell treatment programs. And the last SCD awareness program by the Department of Public Health (DPH) was in 2007.</span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">• A 2013 publication in the journal <i>Blood</i> reported that cystic fibrosis, which affects 30,000 people nationally, receives seven to 11 times more funding per patient than sickle cell disease. The amyotrophic lateral sclerosis (ALS) challenge in 2014 raised more than $115 million for about 20,000 patients in the U.S. The bulk of the funds—$77 million—were allocated for research.</span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div align="center">
<table border="0" cellpadding="0" cellspacing="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td style="padding: 6.75pt 13.5pt 6pt;" valign="top"><div style="line-height: 16.100000381469727px;">
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Sickle Cell Disease Association of America, Inc. </span></b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></div>
<div style="line-height: 16.100000381469727px;">
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Launches Get Connected</span></b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></div>
<div style="line-height: 16.100000381469727px;">
<i><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">First Patient-Powered Registry for Sickle Cell Disease</span></i><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<table align="right" border="0" cellpadding="0" cellspacing="0" class="yiv3454509027MsoNormalTable" style="margin-bottom: 7.75pt; margin-left: 3.75pt; width: 294px;"><tbody>
<tr style="min-height: 0.75pt;"><td style="min-height: 0.75pt; padding: 0in; width: 3.75pt;" valign="top" width="5"><div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"><img alt="https://imgssl.constantcontact.com/letters/images/sys/S.gif" border="0" data-id="909949b1-e6bb-b2f2-09f4-d8b9608c1ad1" height="1" id="yiv3454509027Picture_x0020_21" src="blob:https://www.blogger.com/6ce7cf63-fd58-4477-afd7-a92010b60d12" style="min-height: 0.008in; width: 0.05in;" width="5" /></span><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></div>
</td><td style="min-height: 0.75pt; padding: 0in; width: 289.203125px;" width="100%"><div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"><img alt="http://files.constantcontact.com/a1c20b46201/edd11a18-9114-4e10-a292-ec7e0a30f507.png" border="0" data-id="1d382678-2fe9-0627-ac91-12977b100a18" height="135" id="yiv3454509027Picture_x0020_20" src="blob:https://www.blogger.com/cb4c1826-9475-4e5c-a98f-90a442afb8c7" style="min-height: 1.408in; width: 2.975in;" width="286" /></span><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></div>
</td></tr>
</tbody></table>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Sickle Cell Disease Association of America, Inc. (SCDAA) is officially launching the first patient powered registry for sickle cell disease (SCD) that allows for the <i>secure </i>storage of health information that enables patients to better navigate the health care system and to be counted, showing the number of people living with the disease and the significance of this public health issue. </span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div style="line-height: 16.100000381469727px;">
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">On June 19, World Sickle Cell Day, SCDAA will launch a social media blitz about Get Connected, encouraging individuals to register.</span></b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Get Connected is intended for children and adults with SCD and their families, children and adults with sickle cell trait, health care providers, clinical researchers and advocacy organizations. It provides high quality information about clinical care, research and health advocacy issues related to sickle cell disease and sickle cell trait. It also improves access to disease specific health care and serves as a platform for research initiatives generated by the needs of the SCD patient population.</span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Since 2015, SCDAA has trained its community-based member organizations on Get Connected and the shared measurement system, and has encouraged them to promote the platform in their regions. As of June 5, 2018, 6,128 individuals are enrolled in Get Connected, and 4,984 of those enrolled are patients, 633 are individuals with trait and 511 are non-patients.</span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">"We are very excited to officially launch Get Connected, the first patient powered registry for sickle cell disease, especially on World Sickle Cell Day," said SCDAA President/CEO Beverley Francis-Gibson. "This database provides a significant benefit for the sickle cell community and for our efforts to share information, resources, and to collect data that can be leveraged for advocacy, research and awareness efforts. We encourage individuals to register today."</span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div style="line-height: 16.100000381469727px;">
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Get Connected has several benefits, including:</span></div>
<ul style="margin-bottom: 0in;" type="disc">
<li style="line-height: 16.100000381469727px;"><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Connects those affected by SCD to high quality resources for information on health care, behavioral health, clinical research, and other resources.</span></li>
<li style="line-height: 16.100000381469727px;"><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Establishes a secure network to share information related to clinical care, research, health services, policies, and advocacy.</span></li>
<li style="line-height: 16.100000381469727px;"><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Establishes patient-powered registry for secure storage of medical information related to diagnosis and treatment.</span></li>
</ul>
<div style="line-height: 16.100000381469727px;">
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">To register for Get Connected, visit </span></b><a href="http://r20.rs6.net/tn.jsp?f=001r4zGQpNdB0d88M2hyJF69gePYUOXix7SggnTO7QydKkyNKDzW8lpus1dtUOo4H_oPvq3LRrX6uLPSKDMvqk9VjsXdKrq6DKkKT0ZANXONREtCUVKrUNKLiO9YIn2LzAYiXkYSACk-zGkUXxaY53onGuMybJR7aCkPvQoypBbfLJjmHbO0zkhKw==&c=llLWxDRoGakDa7O6T_uFioG_WBQB2JsRjrIWoZAOdbWGrymNSK0zLA==&ch=6VYLyKk5VFbEU0NxMuo5jSprZVNnnYwZcg8OTfFpNco5Tbpc0aE46w==" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">www.GetConnectedSCD.org</span></b></a><b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">.</span></b></div>
</td></tr>
</tbody></table>
</div>
<div>
<b><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">New Website Global Sickle Cell Disease Network (GSCDN)</span></b><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span><a href="https://www.globalsicklecelldisease.com/" rel="nofollow" style="color: #954f72;" target="_blank"><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">https://www.globalsicklecelldisease.com/</span></a><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> After months of hard work I am very excited to share with you the new and improved </span><a href="https://www.globalsicklecelldisease.com/" rel="nofollow" style="color: #954f72;" target="_blank"><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Global Sickle Cell Disease Network website</span></a><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">. The new website is a platform of resources on sickle cell disease (SCD) treatment, education and research, specifically targeting low and middle-income countries (LMICs).</span></div>
<div>
<span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div>
<span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">I would like to invite you to contribute to the GSCDN’s resource library by sharing resources that are relevant to SCD treatment, education and research in LMICs. Please send resources to </span><a href="mailto:contact.gscdn@sickkids.ca" rel="nofollow" style="color: #954f72;" target="_blank" ymailto="mailto:contact.gscdn@sickkids.ca"><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">contact.gscdn@sickkids.ca</span></a><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">.</span></div>
<div>
<span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div>
<span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">As a top priority of the GSCDN, the new website includes a re-vamped </span><a href="https://www.globalsicklecelldisease.com/treat-centre-maps" rel="nofollow" style="color: #954f72;" target="_blank"><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">interactive map</span></a><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> of sickle cell disease (SCD) treatment centres around the world. The map is a unique resource that identifies locations of treatment centres and provides critical information such as clinical and laboratory services offered at each centre, and contact information at each site. </span></div>
<div>
<span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div>
<span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">I kindly ask all centre contacts to review their site information and let us know if it needs to be updated. We also welcome new sites to be added to our map. Please email </span><a href="mailto:contact.gscdn@sickkids.ca" rel="nofollow" style="color: #954f72;" target="_blank" ymailto="mailto:contact.gscdn@sickkids.ca"><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">contact.gscdn@sickkids.ca</span></a><u><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></u><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">for any questions related to the map. The GSCDN is on Twitter! Follow us </span><a href="https://twitter.com/GlobalSCDN" rel="nofollow" style="color: #954f72;" target="_blank"><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">@GlobalSCDN</span></a><span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">. Join us on Twitter on <b>Thursday June 14</b> as we launch our new website and on <b>Tuesday June 19</b> as we celebrate <b>World Sickle Cell Awareness Day</b>! Please follow us and share the great news and content with your networks! I would like to thank everyone for their continued support in the Global Sickle Cell Disease Network.</span><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">With kind regards,</span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Isaac Odame</span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">Medical Director, The Global Sickle Cell Disease Network</span></div>
<div>
<span lang="EN-CA" style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div>
<span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> </span></div>
<div>
<b><span style="font-family: sans-serif;">IASCNAPA SCHOLARSHIPS</span></b><span style="font-family: sans-serif;">: The International Association of Sickle Cell Nurses and Professional Associates, Inc. (IASCNAPA) has established a college scholarship program to assist individuals living with Sickle Cell Disease who attend an institution of higher learning in the United States. Applicants for IASCNAPA's $1,000 Scholarships must be enrolled in, or have been accepted by, a recognized and accredited post- secondary school, including college, university, trade school, or other institution of higher learning. Curriculum choice, age, gender, race, ethnic background, religion and political affiliation will not be used in evaluating applications. An active IASCNAPA member or a sickle cell disease medical provider must sponsor all applicants. Applications are accepted from March 1 through July 1 of each year. Awards will be given in August of each year. The number of scholarships awarded each year is dependent on available funds and the quality of applications.</span></div>
<div>
<span style="font-family: sans-serif;">IASCNAPA’s funded scholarship awards include:</span></div>
<div>
<span style="font-family: sans-serif;">The Steven Christy Scholarship Fund</span><span style="font-family: sans-serif;"> was established by his wife in memory of her husband, an individual who lived with sickle cell disease and valued education. He struggled to complete college, but persevered and graduated from Fitchburg State University. He spent his career helping others - first as a social worker at Favarh and then as a counselor and coordinator of newborn hemoglobinopathy screening programs at the combined UCONN/St. Francis sickle cell clinic.</span></div>
<div>
<span style="font-family: sans-serif;">The Christine A. Johnson Scholarship Fund</span><span style="font-family: sans-serif;"> was established by the friends of Dr. Christine A. Johnson in her honor. Dr. Christine A Johnson was a provider and advocate for people with sickle cell disease for most of her adult career. She was the founder and Director of the Pediatric Sickle Cell Program at Wake Forest Baptist Medical Center, and an advocate for sickle cell disease for 30 years.</span></div>
<div>
<span style="font-family: sans-serif;">For more information, to donate to the scholarship fund, or to apply for the scholarship, go to </span><a href="http://www.iascnapa.org/" rel="nofollow" style="color: #954f72;" target="_blank"><i><span style="font-family: sans-serif;">www.Iascnapa.org</span></i></a><i><span style="font-family: sans-serif;"></span></i></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<b><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">New video teaching course for CEU/CME:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">REDUCING COMPLICATIONS OF THERAPEUTIC BLOOD TRANSFUSION IN SICKLE CELL DISEASE at </span><a href="http://ghpc.gsu.edu/cme-course-introduction/" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">http://ghpc.gsu.edu/cme-course-introduction/</span></a><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"></span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; font-size: 12pt; padding: 0in;">Articles in the medical literature</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; font-size: 12pt; padding: 0in;"> </span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<b><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">The Anticipatory Politics of Improving Childhood Survival for Sickle Cell Disease</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<b><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">Science, Technology and Human Values</span></b><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"> </span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<a href="http://journals.sagepub.com/doi/abs/10.1177/0162243918778342?journalCode=sthd" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">http://journals.sagepub.com/doi/abs/10.1177/0162243918778342?journalCode=sthd</span></a><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"></span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"> </span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">The article involves social theory, but also incorporates oral histories from longtime researchers in the field. I hope it may eventually be helpful to a broader audience. There are licensing restrictions, but I am allowed to provide a copy directly to interested parties for personal / non-commercial use.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">Gina Jae </span><a href="mailto:ginajae@gmail.com" rel="nofollow" style="color: #954f72;" target="_blank" ymailto="mailto:ginajae@gmail.com"><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">ginajae@gmail.com</span></a><span class="yiv3454509027MsoHyperlink" style="color: #0563c1; text-decoration: underline;"><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"> or </span></span><a href="mailto:gj2008@columbia.edu" rel="nofollow" style="color: #954f72;" target="_blank" ymailto="mailto:gj2008@columbia.edu">gj2008@columbia.edu</a></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; font-size: 12pt; padding: 0in;"> </span></b></div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PLoS One. 2018 Jun 27;13(6):e0199375. doi: 10.1371/journal.pone.0199375. eCollection 2018.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29949647" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Sinha%20CB%5BAuthor%5D&cauthor=true&cauthor_uid=29949647" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Sinha CB</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Bakshi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=29949647" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Bakshi N</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1,2,3,4</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Ross%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29949647" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Ross D</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1,3,4</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Krishnamurti%20L%5BAuthor%5D&cauthor=true&cauthor_uid=29949647" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Krishnamurti L</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1,2,3,4</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Despite its efficacy, the uptake of HU in adults with sickle cell disease (SCD) is poor likely due to a combination of system, provider, and patient-related factors. We investigated attitudes of adult patients towards HU by conducting qualitative interviews with 95 adult SCD patients (age 18 to 67 years old, 71 were female). While 53% of all participants reported that they were currently taking HU, patients ranging in age 18-30 years (Group 1) were more likely to report current HU use as compared to those (Group 2) ranging in age 31-67 years (65% vs. 41% P = 0.01). Most Group 1 participants who reported currently taking HU indicated that the decision to start HU was made by a parent, though some made the decision themselves as a young adult. Group 1 participants expressed trust in the efficacy of HU as well as trust that their physician adequately shared risks and benefits for the medication. The Group 2 participants, who were not currently on HU, were skeptical that all the risks and benefits of HU were known, were concerned that the efficacy of HU was not proven, and that they were not receiving complete information about its potential side effects. Of Group 2 participants who reported currently being on HU, 25% were concerned about the side effects and efficacy of HU and reported continuing HU because of a lack of effective alternatives. These data suggest that there are significant differences by age in adult SCD patients' attitudes towards, utilization and understanding of the risks and benefits of HU.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29949647</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29949647" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"></td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"></td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">2.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Proc Natl Acad Sci U S A. 2018 Jun 26. pii: 201804388. doi: 10.1073/pnas.1804388115. [Epub ahead of print]</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29946035" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Resistance to <i>Plasmodium falciparum</i> in sickle cell trait erythrocytes is driven by oxygen-dependent growth inhibition.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Archer%20NM%5BAuthor%5D&cauthor=true&cauthor_uid=29946035" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Archer NM</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1,2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Petersen%20N%5BAuthor%5D&cauthor=true&cauthor_uid=29946035" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Petersen N</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1,2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Clark%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=29946035" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Clark MA</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Buckee%20CO%5BAuthor%5D&cauthor=true&cauthor_uid=29946035" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Buckee CO</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">3</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Childs%20LM%5BAuthor%5D&cauthor=true&cauthor_uid=29946035" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Childs LM</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">4</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Duraisingh%20MT%5BAuthor%5D&cauthor=true&cauthor_uid=29946035" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Duraisingh MT</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">5</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Sickle cell trait (AS) confers partial protection against lethal <i>Plasmodium falciparum</i> malaria. Multiple mechanisms for this have been proposed, with a recent focus on aberrant cytoadherence of parasite-infected red blood cells (RBCs). Here we investigate the mechanistic basis of AS protection through detailed temporal mapping. We find that parasites in AS RBCs maintained at low oxygen concentrations stall at a specific stage in the middle of intracellular growth before DNA replication. We demonstrate that polymerization of sickle hemoglobin (HbS) is responsible for this growth arrest of intraerythrocytic <i>P. falciparum</i>parasites, with normal hemoglobin digestion and growth restored in the presence of carbon monoxide, a gaseous antisickling agent. Modeling of growth inhibition and sequestration revealed that HbS polymerization-induced growth inhibition following cytoadherence is the critical driver of the reduced parasite densities observed in malaria infections of individuals with AS. We conclude that the protective effect of AS derives largely from effective sequestration of infected RBCs into the hypoxic microcirculation.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29946035</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29946035" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="http://www.pnas.org/cgi/pmidlookup?view=long&pmid=29946035" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for HighWire" border="0" data-id="59a55c57-c3b2-e7a8-8992-f3d2f7e483f1" height="28" id="yiv3454509027Picture_x0020_19" src="blob:https://www.blogger.com/d0d753cd-f742-4941-9207-d7ae6e99db11" style="min-height: 0.291in; width: 1.25in;" width="120" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Conflict of interest statement</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">The authors declare no conflict of interest.</span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">3.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Blood. 2018 Jun 12. pii: blood-2018-03-834440. doi: 10.1182/blood-2018-03-834440. [Epub ahead of print]</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29895661" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">L-glutamine for sickle cell anemia: more questions than answers.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Quinn%20CT%5BAuthor%5D&cauthor=true&cauthor_uid=29895661" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Quinn CT</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">In 2017, the Food and Drug Administration (FDA) approved two medications for sickle cell anemia (SCA): hydroxyurea for children (≥2 years of age) and L-glutamine for children and adults (≥5 years). The approval of hydroxyurea for children was long overdue, having been authorized by the FDA for adults in 1998 and by the European Medicines Agency for adults and children in 2007, but the approval of L-glutamine was a surprise to many in the field. There are few published studies of L-glutamine as a treatment for SCA, so all can be reviewed in this brief manuscript. Accordingly, there are many unanswered questions about L-glutamine and its role in current therapy for SCA.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29895661</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29895661" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=29895661" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for HighWire" border="0" data-id="7d7f26ea-3b35-230d-bffa-3f7a1b6cf36e" height="30" id="yiv3454509027Picture_x0020_18" src="blob:https://www.blogger.com/0cdff98b-63f1-4719-be81-e07935026bfe" style="min-height: 0.308in; width: 1.25in;" width="120" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">4.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Mil Med. 2018 Jun 8. doi: 10.1093/milmed/usy125. [Epub ahead of print]</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29889287" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Association Between Sickle Cell Trait With Selected Chronic Medical Conditions in U.S. Service Members.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Niebuhr%20DW%5BAuthor%5D&cauthor=true&cauthor_uid=29889287" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Niebuhr DW</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20L%5BAuthor%5D&cauthor=true&cauthor_uid=29889287" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Chen L</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Shao%20S%5BAuthor%5D&cauthor=true&cauthor_uid=29889287" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Shao S</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1,2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Goldsmith%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29889287" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Goldsmith J</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">3</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Byrne%20C%5BAuthor%5D&cauthor=true&cauthor_uid=29889287" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Byrne C</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Singer%20DE%5BAuthor%5D&cauthor=true&cauthor_uid=29889287" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Singer DE</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Introduction:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Sickle cell trait (SCT), the heterozygous carrier state for hemoglobin S, is present in an estimated 1.6% of all newborns and 7.3% in black individuals in the USA. SCT has long been considered a benign condition with anticipated normal life expectancy and no increased risk for chronic diseases. The medical literature is inconclusive on the potential association between SCT and chronic medical conditions (CMC) including chronic kidney disease, venous thromboembolism, and stroke. Studies addressing these questions are lacking particularly in non-Black young adults.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Materials and Methods:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">We conducted a retrospective cohort study among U.S. active duty, enlisted, service members who entered from 1992 to 2012 using existing Department of Defense (DoD Military Healthcare System databases). SCT positive subjects (1,323) were matched by demographic characteristics to SCT negative subjects (3,136) and followed through 2013 for CMC that included deep vein thrombosis, diabetes mellitus and hematologic, pulmonary, and renal conditions.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Results:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">The rate of developing any of the included CMC was higher for those with SCT (incidence rate ratio = 1.71 95% CI 1.61-1.81) compared with those who were SCT negative and their healthcare utilization rate for any of CMC studied was higher for SCT positive compared with negative individuals (URR = 2.45 95% CI 2.41-2.50), with the highest rate ratios observed for hematologic and renal conditions. SCT positive compared with negative individuals were more likely to have encounter diagnoses of sickle cell disease and diabetes Type II and were less likely to have encounter diagnoses of other hemoglobinopathies and diabetes type I.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Conclusion:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">SCT in these racially diverse, young adults increased both the incidence of and healthcare utilization for thromboembolism, diabetes mellitus type II, sickle cell disease, pulmonary, and chronic renal conditions. These findings suggest that clinicians treating young adults with SCT should exercise heightened surveillance for these CMC to ensure both early diagnosis and access to treatments.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29889287</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29889287" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://academic.oup.com/milmed/article-lookup/doi/10.1093/milmed/usy125" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Silverchair Information Systems" border="0" data-id="1fd97abd-2091-2db7-314a-9c002c34cb44" height="30" id="yiv3454509027Picture_x0020_17" src="blob:https://www.blogger.com/05a951eb-5b38-4cac-85dc-10d06d965bac" style="min-height: 0.308in; width: 1.25in;" width="120" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">5.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">J Nucl Med. 2018 Jun 7. pii: jnumed.118.211466. doi: 10.2967/jnumed.118.211466. [Epub ahead of print]</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29880507" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Abnormal Ventilation-Perfusion Scan is Associated with Pulmonary Hypertension in Sickle Cell Adults.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Mehari%20A%5BAuthor%5D&cauthor=true&cauthor_uid=29880507" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Mehari A</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Igbineweka%20N%20Dr%5BAuthor%5D&cauthor=true&cauthor_uid=29880507" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Igbineweka N Dr</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Allen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29880507" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Allen D</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Nichols%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29880507" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Nichols J</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Thein%20SL%5BAuthor%5D&cauthor=true&cauthor_uid=29880507" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Thein SL</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Weir%20NA%5BAuthor%5D&cauthor=true&cauthor_uid=29880507" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Weir NA</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Pulmonary hypertension (PH) in adults with sickle cell disease (SCD) is associated with early mortality. Chronic thromboembolic pulmonary hypertension (CTEPH) is an important complication and contributor to PH in SCD, but likely underappreciated. Guidelines recommend ventilation-perfusion scintigraphy (V/Q) as imaging modality of choice to exclude CTEPH. Data on V/Q are limited in SCD. <b>Objective:</b> To compare the performance of V/Q with computed tomography pulmonary angiography (CTPA) and to report clinical outcomes associated with abnormal V/Q. <b>Methods:</b> Laboratory data, echocardiography, six-minute walk test, V/Q, CTPA, and right heart catheterization (RHC) were prospectively obtained. High-probability and intermediate-probability V/Q scan findings were considered to be abnormal. <b>Participants:</b> 142 SCD adults (aged 40.1±13.7 years, 83 women, 87% HbSS) in stable state enrolled consecutively between March 13, 2002 and June 8, 2017 were included for analysis. <b>Results:</b> V/Q scan was abnormal in 65/142 (45.8%). CTPA was positive for pulmonary embolism in 16/60 (26.7%). RHC confirmed PH (mean pulmonary artery pressure (mPAP) ≥25mmHg) in 46/64 (71.9%), of which 34 (73.9%) had abnormal V/Q. Among those without PH by RHC (<i>n</i> = 18), 2/18 patients showed abnormal V/Q. Thirty-three patients had a complete dataset of V/Q, CTPA and RHC; 29/33 had abnormal RHC, of which 26/29 had abnormal V/Q compared to 11/29 with abnormal CTPA. There was a greater concordance of V/Q with RHC (kappa value =0.53; p<0 .001="" compared="" ctpa="" kappa="" rhc="" to="" value="0.13; <i" with="">P</0></span></div>
</td></tr>
</tbody></table>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
= 0.065). The sensitivity and specificity for V/Q was 89.7% and 75.0% respectively, whereas CTPA had sensitivity 37.3% and specificity 100%. Abnormal V/Q was associated with hemodynamic severity (mPA<i>P</i> = 35.2±9.6 vs. 26.9±10.5 mmHg, <i>P</i> = 0.002; transpulmonary gradient 21.5±9.7 vs. 12.16±11mmHg, <i>P</i> = 0.005, and pulmonary vascular resistance=226.5±135 vs.140.7±123.7 dynes.s.cm-5, <i>P</i> = 0.013), and lower exercise capacity (6MWD 382.8±122.3 vs. 442.3±110.6m, p<0 .010="" 15="" abnormal="" all-cause="" compared="" deaths="" group="" higher="" i="" in="" log-rank="" mortality="" nbsp="" normal="" observed="" over="" test="" the="" thirty-four="" to="" v="" was="" were="" years.="">P</0> = 0.006, Hazard Ratio=2.54). <b>Conclusion:</b> V/Q scan is superior to CTPA in detecting thrombotic events in SCD. Abnormal V/Q is associated with PH, worse hemodynamics, lower functional capacity and increased mortality. Despite the high sensitivity of the V/Q scan in detecting CTEPH it is underutilized. We recommend the use of V/Q in the evaluation of dyspnea in SCD adults given the important implications in management.
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29880507</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29880507" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="http://jnm.snmjournals.org/cgi/pmidlookup?view=long&pmid=29880507" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for HighWire" border="0" data-id="d643bf0c-e833-1bf5-9f92-78d6995851eb" height="30" id="yiv3454509027Picture_x0020_16" src="blob:https://www.blogger.com/7bb2a648-075e-4f70-afc6-446f1df80416" style="min-height: 0.308in; width: 1.25in;" width="120" /></span></a><a href="http://emory-primoprod.hosted.exlibrisgroup.com/openurl/01EMORY/01EMORY_services_page?&vid=01EMORY_services_page&sid=Entrez:PubMed&id=pmid:29880507" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Emory University Libraries Electronic Journals" border="0" data-id="f020c775-069d-7051-ac45-cc64c9eee858" height="22" id="yiv3454509027Picture_x0020_15" src="blob:https://www.blogger.com/fd44387a-13d6-49bc-9612-f8c97bfc0825" style="min-height: 0.225in; width: 0.958in;" width="92" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">6.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Cytotherapy. 2018 May 30. pii: S1465-3249(18)30486-9. doi: 10.1016/j.jcyt.2018.04.003. [Epub ahead of print]</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29859773" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Gene therapy for sickle cell disease: An update.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Demirci%20S%5BAuthor%5D&cauthor=true&cauthor_uid=29859773" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Demirci S</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Uchida%20N%5BAuthor%5D&cauthor=true&cauthor_uid=29859773" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Uchida N</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Tisdale%20JF%5BAuthor%5D&cauthor=true&cauthor_uid=29859773" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Tisdale JF</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Sickle cell disease (SCD) is one of the most common life-threatening monogenic diseases affecting millions of people worldwide. Allogenic hematopietic stem cell transplantation is the only known cure for the disease with high success rates, but the limited availability of matched sibling donors and the high risk of transplantation-related side effects force the scientific community to envision additional therapies. Ex vivo gene therapy through globin gene addition has been investigated extensively and is currently being tested in clinical trials that have begun reporting encouraging data. Recent improvements in our understanding of the molecular pathways controlling mammalian erythropoiesis and globin switching offer new and exciting therapeutic options. Rapid and substantial advances in genome engineering tools, particularly CRISPR/Cas9, have raised the possibility of genetic correction in induced pluripotent stem cells as well as patient-derived hematopoietic stem and progenitor cells. However, these techniques are still in their infancy, and safety/efficacy issues remain that must be addressed before translating these promising techniques into clinical practice.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29859773</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29859773" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://linkinghub.elsevier.com/retrieve/pii/S1465-3249(18)30486-9" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Elsevier Science" border="0" data-id="e734ce82-4bb1-9600-70cf-8b6fde76bc61" height="25" id="yiv3454509027Picture_x0020_14" src="blob:https://www.blogger.com/f3910ae2-2365-49e8-bf3e-4cad250b5ebb" style="min-height: 0.258in; width: 1.041in;" width="100" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">7.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Pediatr Blood Cancer. 2018 Jun 1:e27274. doi: 10.1002/pbc.27274. [Epub ahead of print]</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29856534" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">A novel approach to reducing admissions for children with sickle cell disease in pain crisis through individualization and standardization in the emergency department.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Schefft%20MR%5BAuthor%5D&cauthor=true&cauthor_uid=29856534" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Schefft MR</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Swaffar%20C%5BAuthor%5D&cauthor=true&cauthor_uid=29856534" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Swaffar C</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Newlin%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29856534" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Newlin J</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Noda%20C%5BAuthor%5D&cauthor=true&cauthor_uid=29856534" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Noda C</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">3</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Sisler%20I%5BAuthor%5D&cauthor=true&cauthor_uid=29856534" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Sisler I</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">BACKGROUND:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Vaso-occlusive crisis (VOC) is frequent in children with sickle cell disease (SCD) creating significant burden on patients, families, and emergency departments (ED). The objective of the project was to reduce the admission rate for children with SCD presenting to our ED with VOC by >20% within 6 months of initiating individualized pain plans (IPP).</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">METHODS:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">A multi-disciplinary quality improvement team was assembled. A Plan-Do-Study-Act (PDSA) format was employed. The IPP document was created in a unique folder within the electronic medical record. IPPs were created through retrospective chart review for our 80 highest resource users. Pediatric residents, ED residents, and ED attending physicians were instructed on use of the IPPs. Our study measured the presence of an IPP, adherence to the IPP, and time to opiate administration. Our primary outcome was admission rate. Length of stay and 72-hr return to the ED were assessed as balancing measures.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">RESULTS:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Overall, admission rate decreased by 24% following implementation compared with the previous 5 years (P = 0.046). IPPs were created for 78% of patients and followed by ED staff in 86% of visits. Admission rate was significantly lower for patients receiving a second opiate dose within 45 min of the first dose (P < 0.01). There was no difference in readmission rate or 72-hr return rate to ED.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">CONCLUSIONS:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">This study presents an effective strategy to reduce admission rate for children with SCD presenting with VOC. Shorter time to second opiate dosing was also associated with reduced risk of admission.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">© 2018 Wiley Periodicals, Inc.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29856534</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29856534" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="http://dx.doi.org/10.1002/pbc.27274" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Wiley" border="0" data-id="5e827220-ec87-1779-a9eb-fadced4f17c6" height="30" id="yiv3454509027Picture_x0020_13" src="blob:https://www.blogger.com/22699e7f-ad25-4ebd-87ed-471c9f7da8bd" style="min-height: 0.308in; width: 1.25in;" width="120" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">8.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Hematology. 2018 May 31:1-8. doi: 10.1080/10245332.2018.1479997. [Epub ahead of print]</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29848208" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Predictive factors of daily opioid use and quality of life in adults with sickle cell disease.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Karafin%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Karafin MS</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1,2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Singavi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Singavi A</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">3</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hussain%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Hussain J</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">4</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Wandersee%20N%5BAuthor%5D&cauthor=true&cauthor_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Wandersee N</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Heinrich%20T%5BAuthor%5D&cauthor=true&cauthor_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Heinrich T</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">5</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hurley%20RW%5BAuthor%5D&cauthor=true&cauthor_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Hurley RW</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">6</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20L%5BAuthor%5D&cauthor=true&cauthor_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Zhang L</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">7</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Simpson%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Simpson P</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">7</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Field%20JJ%5BAuthor%5D&cauthor=true&cauthor_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Field JJ</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1,3</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">OBJECTIVES:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">In adults with sickle cell disease (SCD), pain often necessitates opioid use. Few studies have examined the relationship between opioid use and health-related quality of life (HRQOL) in adults with SCD. We tested the hypothesis that higher doses of opioids are associated with worse HRQOL.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">METHODS:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">A cross-sectional cohort study was performed in adults with SCD who completed standardized and validated HRQOL questionnaires: Patient Health Questionnaire-15 (PHQ-15), Patient Health Questionnaire-9 (PHQ-9), Medical Outcome Study 36 Item Short Form (SF-36), and Generalized Anxiety Disorder questionnaire (GAD-7). Daily outpatient opioid dose was converted into morphine milligram equivalents (MME) and categorized as < 90 mg/day or ≥ 90 mg/day. Subject's questionnaire scores were compared by opioid dose.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">RESULTS:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Ninety-nine adults completed questionnaires. The majority had HbSS and median age was 30 years. The median MME was 80 mg/day. When the association between HRQOL and opioid dose was compared, those prescribed ≥ 90 MME had significantly lower SF-36 subscale scores in 7 of 8 domains, and significantly higher severity scores in the PHQ-15, GAD-7, and the PHQ-9 in comparison those prescribed < 90 MME. Using a multivariable regression tree analysis, in addition to the presence of chronic pain, mental health, physical health, and somatic burden were key predictors of ≥ 90 MME opioid use.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">CONCLUSION:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Higher daily opioid dose is associated with chronic pain. Among those with chronic pain, opioid dose ≥ 90 MME is associated with worse HRQOL.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29848208</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29848208" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"> also see </span><a href="https://www.clinicalpainadvisor.com/chronic-pain/sickle-cell-disease-chronic-pain-opioid-dosage-health-related-quality-of-life/article/776851/" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">https://www.clinicalpainadvisor.com/chronic-pain/sickle-cell-disease-chronic-pain-opioid-dosage-health-related-quality-of-life/article/776851/</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="http://www.tandfonline.com/doi/full/10.1080/10245332.2018.1479997" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Taylor & Francis" border="0" data-id="c866f2f3-e4be-e228-aeca-3cda832cbcd4" height="30" id="yiv3454509027Picture_x0020_12" src="blob:https://www.blogger.com/7919adcb-50b3-423c-8283-b36c8aba666c" style="min-height: 0.308in; width: 1.25in;" width="120" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">9.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Prof Case Manag. 2018 Jul/Aug;23(4):213-219. doi: 10.1097/NCM.0000000000000260.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29846351" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Barriers to Care for Persons With Sickle Cell Disease: The Case Manager's Opportunity to Improve Patient Outcomes.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Brennan-Cook%20J%5BAuthor%5D&cauthor=true&cauthor_uid=29846351" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Brennan-Cook J</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Bonnabeau%20E%5BAuthor%5D&cauthor=true&cauthor_uid=29846351" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Bonnabeau E</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Aponte%20R%5BAuthor%5D&cauthor=true&cauthor_uid=29846351" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Aponte R</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Augustin%20C%5BAuthor%5D&cauthor=true&cauthor_uid=29846351" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Augustin C</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Tanabe%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29846351" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Tanabe P</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PURPOSE AND OBJECTIVES:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">The purpose of this discussion is to review the barriers to care for patients with sickle cell disease (SCD). Chronic pain and the perception of addiction, implicit bias, frequent hospitalizations and emergency department visits, clinician and patient knowledge deficits, and SCD stigma all impede the ability to provide evidence-based care for patients with SCD. Case managers can coordinate and advocate for appropriate care that improves patient outcomes.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PRIMARY PRACTICE SETTING:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">This discussion is relevant to case managers working with patients with SCD in the clinic, hospital, and emergency department.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">FINDINGS/CONCLUSIONS:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Case managers can serve an important advocacy role and intervene to improve the coordination of services and efficient use of resources. This will lead to improved quality of life and optimal health care utilization for persons with SCD.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">IMPLICATIONS FOR CASE MANAGEMENT PRACTICE:</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">As a constant member of the health care team, the case manager may be the only health care team member who has a broad knowledge of the patient's experience of acute and chronic pain, usual state of health, social behavioral health needs, and how these factors may affect both inpatient and outpatient health care use and health outcomes. This article explores the barriers to care and suggests specific interventions within the role of the case manager that can improve care delivered and ultimately contribute to improved patient outcomes. Specifically, these interventions can improve communication among members of the health care team. Case manager interventions can guide coordination, prevent hospital readmissions, reduce health care utilization, and contribute to overall improved patient quality of life and health outcomes.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMCID: PMC5981859 [Available on 2019-07-01]</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29846351</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29846351" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="http://insights.ovid.com/pubmed?pmid=29846351" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Wolters Kluwer" border="0" data-id="0cf63791-985a-284d-aced-ba6b709401b9" height="30" id="yiv3454509027Picture_x0020_11" src="blob:https://www.blogger.com/cc6e00ee-b5d6-4751-bfd3-d353d3c3cb1b" style="min-height: 0.308in; width: 1.25in;" width="120" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">10.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Transfus Med. 2018 May 29. doi: 10.1111/tme.12543. [Epub ahead of print]</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29845661" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">The erythrocyte alloimmunisation in patients with sickle cell anaemia: a systematic review.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=da%20Cunha%20Gomes%20EG%5BAuthor%5D&cauthor=true&cauthor_uid=29845661" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">da Cunha Gomes EG</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Machado%20LAF%5BAuthor%5D&cauthor=true&cauthor_uid=29845661" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Machado LAF</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Oliveira%20LC%5BAuthor%5D&cauthor=true&cauthor_uid=29845661" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">de Oliveira LC</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Neto%20JFN%5BAuthor%5D&cauthor=true&cauthor_uid=29845661" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Neto JFN</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">3</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Transfusion therapy is a common practice in the treatment of anaemia and can cause erythrocyte alloimmunisation. To systematise data related to erythrocyte alloimmunisation in patients with sickle cell disease (SCD). A bibliographic search was carried out in September 2017 to search for studies in four electronic databases. (i) Referring to the original work, (ii) being cohort or case-control, (iii) having been developed with individuals with SCD and (iv) having evaluated the erythrocyte alloimmunisation. Two reviewers identified the articles for inclusion in the study, extracted the predetermined data and carried out the evaluation of the methodological quality of the work. 21 studies were selected; the studies included data on 20 636 individuals (children and adults), were mostly published in the last 10 years, were developed in the United States and had high methodological quality. The occurrence of erythrocyte alloimmunisation ranged from 4·4 to 76%, and there was a higher rate of alloimmunisation against antigens of the Rh system. The risk factors for alloimmunisation were age; gender (female); red blood cell (RBC) units received; presence of ≥1 autoantibodies, TNF-α, interleukin (IL1B), human leukocyte antigens (HLA)-DRB1 gene polymorphisms; first blood transfusion (BT) after 5 years of age, transfusion episodic, multiple or during inflammatory events, acute chest syndrome (ACS) and vase-occlusive crisis (VOC); increased percentage of CD41 T memory cells; and positive direct antiglobulin test. Transfusion policies should be developed to protect the patient and his or her health based on the main factors associated with its incidence.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29845661</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29845661" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="http://dx.doi.org/10.1111/tme.12543" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Wiley" border="0" data-id="c9a654a4-df1e-b1fc-e1d2-4a5d2d5c9b74" height="30" id="yiv3454509027Picture_x0020_10" src="blob:https://www.blogger.com/22699e7f-ad25-4ebd-87ed-471c9f7da8bd" style="min-height: 0.308in; width: 1.25in;" width="120" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">11.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Exp Hematol. 2018 May 26. pii: S0301-472X(18)30264-9. doi: 10.1016/j.exphem.2018.05.004. [Epub ahead of print]</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29807062" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Sii-Felice%20K%5BAuthor%5D&cauthor=true&cauthor_uid=29807062" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Sii-Felice K</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Giorgi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=29807062" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Giorgi M</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Leboulch%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29807062" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Leboulch P</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Payen%20E%5BAuthor%5D&cauthor=true&cauthor_uid=29807062" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Payen E</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">3</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">The β-hemoglobinopathies, transfusion-dependent β-thalassemia and sickle cell disease, are the most prevalent inherited disorders worldwide and affect millions of people. Many of these patients have a shortened life expectancy and suffer from severe morbidity despite supportive therapies, which impose an enormous financial burden to societies. The only available curative therapy is allogeneic hematopoietic stem cell transplantation, although most patients do not have an HLA-matched sibling donor, and those who do still risk life-threatening complications. Therefore, gene therapy by one-time ex vivo modification of hematopoietic stem cells followed by autologous engraftment is an attractive new therapeutic modality. The first proof-of-principle of conversion to transfusion independence by means of a lentiviral vector expressing a marked and anti-sickling β<sup>T87Q</sup>-globin gene variant was reported a decade ago in a patient with transfusion-dependent β-thalassemia. In follow-up multicenter Phase II trials with an essentially identical vector (termed LentiGlobin BB305) and protocol, 12 of the 13 patients with a non-β<sup>0</sup>/β<sup>0</sup> genotype, representing more than half of all transfusion-dependent β-thalassemia cases worldwide, stopped red blood cell transfusions with total hemoglobin levels in blood approaching normal values. Correction of biological markers of dyserythropoiesis was achieved in evaluated patients. In nine patients with β<sup>0</sup>/β<sup>0</sup> transfusion-dependent β-thalassemia or equivalent severity (β<sup>IVS1-110</sup>), median annualized transfusion volume decreased by 73% and red blood cell transfusions were stopped in three patients. Proof-of-principle of therapeutic efficacy in the first patient with sickle cell disease was also reported with LentiGlobin BB305. Encouraging results were presented in children with transfusion-dependent β-thalassemia in another trial with the GLOBE lentiviral vector and several other gene therapy trials are currently open for both transfusion-dependent β-thalassemia and sickle cell disease. Phase III trials are now under way and should help to determine benefit/risk/cost ratios to move gene therapy toward clinical practice.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29807062</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29807062" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://linkinghub.elsevier.com/retrieve/pii/S0301-472X(18)30264-9" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Elsevier Science" border="0" data-id="03339aeb-e26f-ae41-cb5a-36955b2e496c" height="25" id="yiv3454509027Picture_x0020_9" src="blob:https://www.blogger.com/f3910ae2-2365-49e8-bf3e-4cad250b5ebb" style="min-height: 0.258in; width: 1.041in;" width="100" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">12.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">J Health Care Poor Underserved. 2018;29(2):814-829. doi: 10.1353/hpu.2018.0060.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29805142" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Social and Behavioral Factors in Sickle Cell Disease: Employment Predicts Decreased Health Care Utilization.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Williams%20H%5BAuthor%5D&cauthor=true&cauthor_uid=29805142" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Williams H</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Silva%20RNS%5BAuthor%5D&cauthor=true&cauthor_uid=29805142" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Silva RNS</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Cline%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29805142" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Cline D</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Freiermuth%20C%5BAuthor%5D&cauthor=true&cauthor_uid=29805142" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Freiermuth C</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Tanabe%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29805142" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Tanabe P</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">to determine frequency of health care encounters among people with sickle cell disease (SCD) seeking treatment for a vaso-occlusive crisis (VOC). Health care encounters are categorized by visit type (day hospital, ED visit, hospitalization), prevalence of self-reported behavioral and social factors, and any associations between behavioral and social factors and health care encounters. Ninety-five people with SCD were enrolled in a prospective descriptive study in North Carolina. Patients were interviewed concerning behavioral-social factors, and a report of health care encounters was produced, generated by ICD codes associated with VOCs between October 2011 and March 2014. Among 95 patients, there were a total of 839 day hospital and 1,990 ED visits, and 1,101 hospital admissions. Prevalent behavioral and social factors were depression (29%), anxiety (34%), illicit drug use (6%); unstable home situation (17%); and unemployment (81%). Employment and stable home were significantly associated with decreased frequency of health care encounters.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29805142</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29805142" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="http://muse.jhu.edu/cgi-bin/resolve_openurl.cgi?issn=1049-2089&volume=29&issue=2&spage=814&aulast=Williams" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Project MUSE" border="0" data-id="62cc6c21-76ba-5566-87fa-80d23010d2a7" height="35" id="yiv3454509027Picture_x0020_8" src="blob:https://www.blogger.com/118b05d1-bcf3-4e4f-be2e-23ae06fcb24b" style="min-height: 0.366in; width: 1.333in;" width="128" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">13.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Pediatr Clin North Am. 2018 Jun;65(3):427-443. doi: 10.1016/j.pcl.2018.01.005.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29803275" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Treatment Options for Sickle Cell Disease.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Meier%20ER%5BAuthor%5D&cauthor=true&cauthor_uid=29803275" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Meier ER</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Sickle cell disease (SCD) complications begin with the polymerization of sickle hemoglobin (HbS). Thus, SCD therapies are focused on preventing HbS production or reducing the circulating amount of HbS. Hydroxyurea treatment has become more widespread, whereas the number of evidence-based indications for erythrocyte transfusion is small. Hematopoietic stem cell transplant is a curative option for SCD but less than 25% of patients have a suitable donor. This article focuses on supportive and preventive care improvements and the benefits of hydroxyurea. Indications for erythrocyte transfusion, hematopoietic stem cell transplant, and gene therapy trials are also summarized.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29803275</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29803275" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://linkinghub.elsevier.com/retrieve/pii/S0031-3955(18)30005-1" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Elsevier Science" border="0" data-id="578557c7-d95d-ed64-dfaf-07c3d1f005ad" height="25" id="yiv3454509027Picture_x0020_7" src="blob:https://www.blogger.com/f3910ae2-2365-49e8-bf3e-4cad250b5ebb" style="min-height: 0.258in; width: 1.041in;" width="100" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">14.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Pediatr Clin North Am. 2018 Jun;65(3):445-464. doi: 10.1016/j.pcl.2018.01.006.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29803276" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">A Scientific Renaissance: Novel Drugs in Sickle Cell Disease.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Zaidi%20AU%5BAuthor%5D&cauthor=true&cauthor_uid=29803276" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Zaidi AU</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Heeney%20MM%5BAuthor%5D&cauthor=true&cauthor_uid=29803276" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Heeney MM</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">We have entered an era of exploding interest in therapeutics for sickle cell disease. The expansion in our understanding of sickle cell disease pathophysiology has enhanced the range of potential therapeutic targets. From induction of fetal hemoglobin to antiadhesion molecules, we are potentially on the cusp of making life-altering modifications for individuals with sickle cell disease. This disease population cannot afford to let the current momentum wane. Studies exploring combinations of therapies affecting multiple steps in the pathophysiology and exploring novel and clinically relevant outcomes are incumbent.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29803276</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29803276" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://linkinghub.elsevier.com/retrieve/pii/S0031-3955(18)30006-3" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Elsevier Science" border="0" data-id="b50a40d8-fc14-016d-aeb0-6d8cec31ac07" height="25" id="yiv3454509027Picture_x0020_6" src="blob:https://www.blogger.com/f3910ae2-2365-49e8-bf3e-4cad250b5ebb" style="min-height: 0.258in; width: 1.041in;" width="100" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">15.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Pediatr Clin North Am. 2018 Jun;65(3):465-480. doi: 10.1016/j.pcl.2018.01.008.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29803277" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Genetic Therapies for Sickle Cell Disease.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Jayavaradhan%20R%5BAuthor%5D&cauthor=true&cauthor_uid=29803277" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Jayavaradhan R</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Malik%20P%5BAuthor%5D&cauthor=true&cauthor_uid=29803277" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Malik P</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Sickle cell disease is the most prevalent monogenic disorder worldwide and curative therapies are limited to hematopoietic stem cell transplant to the few with matched donors. Gene therapy has curative potential, whereby autologous hematopoietic stem cells are genetically modified and transplanted, which would not be limited by matched donors, resulting in 1-time, life-long correction devoid of immune side effects. Significant progress has been made to clinically translate gene therapy for sickle cell disease using lentivirus vectors carrying antisickling genes. This review focuses on the current state of the field, factors that determine clinical success, gene editing, and future prospects.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29803277</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29803277" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://linkinghub.elsevier.com/retrieve/pii/S0031-3955(18)30008-7" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Elsevier Science" border="0" data-id="a89b8d56-c6ed-dda4-aaed-e0a60842a262" height="25" id="yiv3454509027Picture_x0020_5" src="blob:https://www.blogger.com/f3910ae2-2365-49e8-bf3e-4cad250b5ebb" style="min-height: 0.258in; width: 1.041in;" width="100" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
</div>
<table border="0" cellpadding="0" class="yiv3454509027MsoNormalTable" style="width: 100%px;"><tbody>
<tr><td nowrap="" style="padding: 0in; width: 7.5pt;" valign="top" width="10"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">16.</span></div>
</td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Pediatr Clin North Am. 2018 Jun;65(3):481-493. doi: 10.1016/j.pcl.2018.01.007.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29803278" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">The Epidemiology and Management of Lung Diseases in Sickle Cell Disease: Lessons Learned from Acute and Chronic Lung Disease in Cystic Fibrosis.</span></b></a><b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Willen%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=29803278" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Willen SM</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">1</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">, </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=DeBaun%20MR%5BAuthor%5D&cauthor=true&cauthor_uid=29803278" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">DeBaun MR</span></a><sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">2</span></sup><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">.</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Abstract</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">Although sickle cell disease and cystic fibrosis are two of the most common monogenic diseases presenting in childhood worldwide, cystic fibrosis and sickle cell disease enjoy vastly different funding and collaborative research efforts. Pulmonary complications in cystic fibrosis have well established guidelines and multidisciplinary involvement focusing on comorbidities, routine monitoring, infectious complications, nutrition, and treatment recommendations. These guidelines can provide a framework on which to build knowledge of lung disease in sickle cell disease.</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;" valign="top"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<span style="color: #212121; font-family: sans-serif; font-size: 12pt;">PMID: 29803278</span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://www.ncbi.nlm.nih.gov/pubmed?linkname=pubmed_pubmed&from_uid=29803278" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif; font-size: 12pt;">Similar articles</span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
<tr><td style="padding: 0in; width: 7.5pt;" valign="top" width="10"></td><td style="padding: 0in;"><div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<a href="https://linkinghub.elsevier.com/retrieve/pii/S0031-3955(18)30007-5" rel="nofollow" style="color: #954f72;" target="_blank"><span style="color: #212121; font-family: sans-serif; font-size: 12pt; text-decoration: none;"><img alt="Icon for Elsevier Science" border="0" data-id="1d42a0c3-f9b9-9ff3-bd4b-283172348662" height="25" id="yiv3454509027Picture_x0020_4" src="blob:https://www.blogger.com/f3910ae2-2365-49e8-bf3e-4cad250b5ebb" style="min-height: 0.258in; width: 1.041in;" width="100" /></span></a><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"></span></div>
</td></tr>
</tbody></table>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="color: #212121; font-family: sans-serif; font-size: 12pt;"> </span></b><b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; font-size: 12pt; padding: 0in;">Sickle Cell Conferences and Events</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 14.4pt; margin: 0in 0in 0pt; vertical-align: baseline;">
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; font-size: 12pt; padding: 0in;"> </span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 15pt; margin: 0in 0in 10pt;">
<b><span style="color: #1d2129; font-family: sans-serif; font-size: 12pt;">2018 Sickle Cell in Focus October 22-23, 2018 National Institutes of Health Natcher Conference Center Bethesda, MD 20892</span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 15pt; margin: 0in 0in 10pt;">
<a href="https://www.eventbrite.com/e/sickle-cell-in-focus-2018-registration-45769952159" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">Click here for event details and to register!</span></b></a><b><span style="color: #1d2129; font-family: sans-serif; font-size: 12pt;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 15pt; margin: 0in 0in 10pt;">
<a href="https://www.nhlbi.nih.gov/events/2018/sickle-cell-focus-conference-2018#Event-Details" rel="nofollow" style="color: #954f72;" target="_blank"><b><span style="font-family: sans-serif; font-size: 12pt;">To view the agenda click here.</span></b></a><b><u><span style="color: #1d2129; font-family: sans-serif; font-size: 12pt;"></span></u></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 15pt; margin: 0in 0in 10pt;">
<strong><span style="font-family: sans-serif;"> </span></strong></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 15pt; margin: 0in 0in 10pt;">
<strong><span style="color: #1d2129; font-family: sans-serif; font-size: 12pt;">46TH ANNUAL NATIONAL CONVENTION THEME ANNOUNCED</span></strong><span style="font-family: sans-serif; font-size: 12pt;">This year's theme for the conference is <em><b>Celebrating the Diversity Within the Sickle Cell Community: Commitment, Innovation, and Practice</b></em></span><em><span style="font-family: sans-serif;"></span></em></div>
<div>
<span style="font-family: sans-serif;">With over 600 researchers, physicians, nurses, social workers, individuals living with SCD & SCT in attendance, last year’s year’s convention was a major success and our largest to date. We are excited to unite again with you at the 46th Annual National Convention in Baltimore, MD on October 10-13, 2018!</span><a href="https://www.sicklecelldisease.org/2017/03/07/46th-annual-national-convention/" rel="nofollow" style="color: #954f72;" target="_blank"><span style="font-family: sans-serif;">https://www.sicklecelldisease.org/2017/03/07/46th-annual-national-convention/</span></a></div>
<div>
<b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;">The 4<sup>th</sup> Annual Sickle Cell Disease Symposium for Carolinas Healthcare System - Atrium Health</span></b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"> will be held on <b>Saturday, October 27, 2018 </b>at the <b>Speedway Club</b> in Charlotte, NC. The theme this year is: <b>“4<sup>th</sup> Annual SCD Symposium: Racing to Improve the Access to Care & Outcomes for SCD”.</b></span><b><span style="border-image-source: none; border: 1pt windowtext; font-family: sans-serif; padding: 0in;"></span></b></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 12pt;">
<b><span lang="EN-CA" style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">2018 (Re) imagining Health: Sickle Cell Anemia & Thalassaemia: An International Biomedical-Sociocultural Conference</span></b><span lang="EN-CA" style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"> <b>November 16 - 17, 2018</b><br /><b>Edmonton Clinic Health Academy, University of Alberta Edmonton, Alberta, Canada - </b>This event will join our community of physicians, surgeons, researchers, medical practitioners and patients with a deep understanding and commitment to finding the cure for Sickle Cell Anemia.</span><span style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"></span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<span lang="EN-CA" style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">We aim to bring together multiple voices to support and build inclusive and equitable teaching and learning environments, while increasing knowledge of the continued effects of the Sickle Cell Anemia trait. The Sickle Cell Foundation of Alberta is proud to announce the following expert speakers</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<span lang="EN-CA" style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">Dr. Lakiea Bailey, of Georgia, USA<br />Dr. Carl James, of Toronto, ON<br />Dr. Emily Meier of Indiana, USA<br />Dr. Greg Guilcher of Calgary, AB<br />Dr. Santosh Saraf of Illinois, USA<br />Dr. Courtney Fitzhugh of Maryland, USA</span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<b><span lang="EN-CA" style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">REGISTRATION -</span></b><span lang="EN-CA" style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"> </span><span lang="EN-CA" style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">Conference registration is now open. A variety of registration categories are available for the conference. Please see the fee details below or register online <span class="yiv3454509027MsoHyperlink" style="color: #0563c1; text-decoration: underline;"><a href="https://events.r20.constantcontact.com/register/eventReg?oeidk=a07efbitlri6ad273d2&oseq=&c=&ch=" rel="nofollow" style="color: #954f72;" target="_blank">here.</a> </span></span><u><span style="color: blue; font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"><a href="https://ourscfa.org/conference/" rel="nofollow" style="color: #954f72;" target="_blank">https://ourscfa.org/conference/</a></span></u><span lang="EN-CA" style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;"></span></div>
<div class="yiv3454509027MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; line-height: 16.866666793823242px; margin: 0in 0in 10pt;">
<span lang="EN-CA" style="font-family: sans-serif; font-size: 12pt; line-height: 18.399999618530273px;">More information can be found on the conference website<br /><span class="yiv3454509027MsoHyperlink" style="color: #0563c1; text-decoration: underline;"><a href="https://www.blogger.com/blogger.g?blogID=5059039568754833581" rel="nofollow" style="color: #954f72;">www.ourscfa.org/conference</a> </span>Contact us at <span class="yiv3454509027MsoHyperlink" style="color: #0563c1; text-decoration: underline;"><a href="mailto:SCFA@buksa.com?subject=SCFA%20(Re)Imagining%20Health,%20Online%20Enquiry%20" rel="nofollow" style="color: #954f72;" target="_blank" ymailto="mailto:SCFA@buksa.com?subject=SCFA%20(Re)Imagining%20Health,%20Online%20Enquiry%20">SCFA@buksa.com</a></span></span></div>
Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com2tag:blogger.com,1999:blog-5059039568754833581.post-19105917882028577152012-04-12T20:16:00.001-04:002012-04-12T20:16:35.269-04:00"Be The Match"BE THE ONE RUN Richmond Virginia April 21st 2012<br />
<a href="http://www.wric.com/global/Category.asp?c=190525&autoStart=true&topVideoCatNo=default&clipId=6936448#.T4dwOrMemzM.blogger">"Be The Match"</a>Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-67823813652033552742012-02-28T11:31:00.001-05:002012-02-28T11:34:52.866-05:00Be the ONE Run Richmond, Virginia!Greeting<br />Friends and Family,<br /><br />The<br />message below is an abbreviated story. Also feel free to forward to<br />others who would show support.<br />When<br />you have a chance please visit the link below to read the whole story it will<br />inspire and uplift.<br /><br /><a href="http://www.bethematchfoundation.org/goto/Ron" target="_blank">http://www.bethematchfoundation.org/goto/Ron</a><br /><br />My<br />mother (Rosamond Dews) passed away from Leukemia in January of 2000. A<br />life giving procedure called bone marrow transplant could have saved<br />her life. In December of 2004, I (Ronald Dews Jr.) was a match and gave<br />bone marrow to a 15 year girl with Leukemia which saved her life.<br />I have 2 sons (Riley 5 and Tracy 9) who have Sickle Cell Disease and research<br />shows that in the near future bone marrow transplants may save<br />their lives.<br /><br />Support<br />saving my families legacy and Join or Donate for the upcoming Be The One Run in<br />Richmond, Virginia!<br /><br />Ron Dews <a href="tel:804-852-4420" target="_blank" value="+18048524420">804-852-4420</a><br />Be The One<br />Run is a run/walk fundraising event that gives patients with leukemia, sickle<br />cell and 70 other life‐threatening<br />diseases a second chance at life. Every step participants take helps<br />patients receive the marrow transplant they need.<br />The<br />Richmond Be The One Run is April 21, 2012, and will include a 5K, 1K, and Tot<br />Trot.Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com1tag:blogger.com,1999:blog-5059039568754833581.post-44721304488237503732011-11-23T12:59:00.005-05:002011-11-23T13:16:50.947-05:00Skipwith Elementary School - 11/18 Tracy Dews<a href="http://3.bp.blogspot.com/-YVWtAs2R79c/Ts028IJHOeI/AAAAAAAAAQ4/mv5whgc76SM/s1600/IMG-20111123-00017.jpg"><img id="BLOGGER_PHOTO_ID_5678255111789820386" style="WIDTH: 320px; CURSOR: hand; HEIGHT: 240px" alt="" src="http://3.bp.blogspot.com/-YVWtAs2R79c/Ts028IJHOeI/AAAAAAAAAQ4/mv5whgc76SM/s320/IMG-20111123-00017.jpg" border="0" /></a><br />CLICK LINK BELOW TO SEE VIDEO<br /><a href="http://www.henrico.k12.va.us/hcpstv/TC-Skipwith.html">http://www.henrico.k12.va.us/hcpstv/TC-Skipwith.html</a><br /><br /><a href="http://1.bp.blogspot.com/-CqZfF2NMr34/Ts003rWPwoI/AAAAAAAAAQs/dfe6GHocbsE/s1600/TCheader.jpg"><img id="BLOGGER_PHOTO_ID_5678252836317545090" style="WIDTH: 320px; CURSOR: hand; HEIGHT: 79px" alt="" src="http://1.bp.blogspot.com/-CqZfF2NMr34/Ts003rWPwoI/AAAAAAAAAQs/dfe6GHocbsE/s320/TCheader.jpg" border="0" /></a><br /><br /><div></div><br /><br /><div>View episodes of TODAY'S CLASSROOM here! </div><br /><br /><br /><br /><p>Tracy John Dews class has a science lesson on measurment</p><br /><p></p><br /><p>1 Gallon = 4 Quarts = 8 pints = 16 cups</p>1 Gallon Kingdon = 4 Queens = 8 Princesses = 16 crowns<br /><br /><br /><br /><p>The Gallon Kingdom of measurement</p><br /><p>1 Gallon Kingdom has 4 Queens, </p><br /><p>2 + 2 Queens</p><br /><p>2+2+2+2 Princess </p><br /><p>2+2+2+2+2+2+2+2 Crowns</p>Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-78757698372471667252011-09-01T10:22:00.003-04:002011-09-01T10:34:53.781-04:00Tiffany Dews Tracy Dews Riley Dews featured on Children’s Miracle Network Hospitals Radiothon<a href="http://1.bp.blogspot.com/-Y2atcGhuFvE/Tl-X10VY4yI/AAAAAAAAAQg/O7yMtx_m9qA/s1600/CMN2.jpg"><img id="BLOGGER_PHOTO_ID_5647399408583107362" style="WIDTH: 320px; CURSOR: hand; HEIGHT: 134px" alt="" src="http://1.bp.blogspot.com/-Y2atcGhuFvE/Tl-X10VY4yI/AAAAAAAAAQg/O7yMtx_m9qA/s320/CMN2.jpg" border="0" /></a>
<br />
<br /><div>
<br />
<br /><div>Children’s Miracle Network Hospitals, 98.9 Liberty and Big Oldies 107.3 are joining together again to help local kids.
<br />On September 1st and 2nd, we invite you to tune your radios to 98.9 Liberty and Big Oldies 107.3 for the
<br />2ND ANNUALChildren’s Miracle Network Hospitals Radiothon September 1 and September 2, 20117:00 am to 7:00 p.m. each dayDonate during Radiothon by calling (804) 228-5888Local DJ personalities Johnny Mack, Tony Booth, Jim Conlee and Jen Towner will broadcast incredible stories of brave children LIVE from Children's Hospital of Richmond's Brook Road Campus.Radiothon, presented by Martin's, is a celebration of the miracles that happen each and every day at our local Children’s Miracle Network Hospital. We invite you to consider making a donation and help us continue providing the health care our children need and deserve.Go ahead, tune in to radio so powerful it makes miracles!<a href="http://cts.vresp.com/c/?ChildrensHospitalFou/7a169a0f9c/779703ea0b/1848ebd3e1/fuseaction=donordrive.eventDetails&eventID=948%20%20">Click here for a sneak peak of some of the amazing stories you’ll hear or to make a secure online donation with a credit card >></a>Please feel free to share this email with friends and family! For more information, contact 804-228-5929.</div>
<br /><a href="http://3.bp.blogspot.com/-n5Q_1UAq1YA/Tl-Xf6uKxFI/AAAAAAAAAQY/ds7T_mAbe2Y/s1600/CMN1.bmp"><img id="BLOGGER_PHOTO_ID_5647399032340530258" style="WIDTH: 320px; CURSOR: hand; HEIGHT: 234px" alt="" src="http://3.bp.blogspot.com/-n5Q_1UAq1YA/Tl-Xf6uKxFI/AAAAAAAAAQY/ds7T_mAbe2Y/s320/CMN1.bmp" border="0" /></a>
<br />
<br />
<br />
<br /><div></div>
<br />
<br />
<br />
<br />
<br /><div></div></div>
<br />Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-38132726073313426172011-03-02T11:49:00.001-05:002011-03-02T12:00:17.234-05:00Patient Voices: Sickle Cell Anemia<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhxyBF0ulr9J5Aa4GZSMIBbhEySqrVr9rGLfnAmYgFhdYd0zJjyG0PYKSJqBrrDrURzsw2iiimXcnP09B4XT1_Sz76TYylrWzRxnRvAc850b07I5tBlOArOWmbDV7AZXJ-0FabgOqWQKeo/s1600/01sicklecell-blog480.jpg"><img id="BLOGGER_PHOTO_ID_5579528486111221618" style="DISPLAY: block; MARGIN: 0px auto 10px; WIDTH: 320px; CURSOR: hand; HEIGHT: 214px; TEXT-ALIGN: center" alt="" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhxyBF0ulr9J5Aa4GZSMIBbhEySqrVr9rGLfnAmYgFhdYd0zJjyG0PYKSJqBrrDrURzsw2iiimXcnP09B4XT1_Sz76TYylrWzRxnRvAc850b07I5tBlOArOWmbDV7AZXJ-0FabgOqWQKeo/s320/01sicklecell-blog480.jpg" border="0" /></a><br /><p>FULL AUDIO and VIDEO</p><br /><p><a href="http://www.nytimes.com/interactive/2011/03/02/health/healthguide/te_sicklecell.html?ref=health">http://www.nytimes.com/interactive/2011/03/02/health/healthguide/te_sicklecell.html?ref=health</a></p><br /><p><a href="http://health.nytimes.com/health/guides/disease/sickle-cell-anemia/overview.html?WT.z_gsac=1" target="_blank">Sickle cell anemia</a> is an inherited disease in which red blood cells are unable to properly carry oxygen throughout the body because of their distinctive crescent-like, or sickle, shape. The condition causes severe episodes of pain and fatigue, and it can lead to damage to the eyes and other organs. Sickle cell anemia affects about 72,000 people in the United States, most of African descent. Here, six men and women speak about the impact sickle cell anemia has had on their lives and families. (Join the discussion <a href="http://well.blogs.nytimes.com/2011/03/02/the-voices-of-sickle-cell-disease/" target="_blank">here.)</a></p><br /><div></div><br /><div></div>Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com1tag:blogger.com,1999:blog-5059039568754833581.post-85319747491498011992011-02-11T10:56:00.002-05:002011-02-11T11:00:24.385-05:00Dews Family interviewed for Sickle Cell Article<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgN7dge6vHpShABKEoBKu6eEhgT7JxvG8i_t_Ks5I_ESsNRlTW_g50KCf6Jk7TCnqdFFyXsM1hwe1W_N49B60N-1kyEhF5DgVu_e4hkTwT1P2dA6D2pOjEy8-NkQBxpTQ3Go1ZGsj8moW8/s1600/110207_DewsFamily.jpg"><img id="BLOGGER_PHOTO_ID_5572462410872485154" style="DISPLAY: block; MARGIN: 0px auto 10px; WIDTH: 320px; CURSOR: hand; HEIGHT: 214px; TEXT-ALIGN: center" alt="" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgN7dge6vHpShABKEoBKu6eEhgT7JxvG8i_t_Ks5I_ESsNRlTW_g50KCf6Jk7TCnqdFFyXsM1hwe1W_N49B60N-1kyEhF5DgVu_e4hkTwT1P2dA6D2pOjEy8-NkQBxpTQ3Go1ZGsj8moW8/s320/110207_DewsFamily.jpg" border="0" /></a><br /><div>Monday February 7, 2011 the Dews family was interviewed and photographed by Casey Templeton for a audio diary and interent article which bring a spotlight on Sickle Cell and the families story. I will provide an update when the article is released.</div><br /><div></div>Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com1tag:blogger.com,1999:blog-5059039568754833581.post-8645041753239552562010-07-07T14:30:00.003-04:002010-07-07T14:43:57.512-04:00Another way to help Sickle Cell Patients "Donate Platelets"<a href="http://1.bp.blogspot.com/_Xlazsp1mHx0/TDTKfThtBYI/AAAAAAAAAKc/ilvA5lrc1qQ/s1600/A%2520Neg%2520and%2520B%2520Neg%2520Special%2520Need%2520Web%2520Banner.jpg"><img id="BLOGGER_PHOTO_ID_5491236484837868930" style="DISPLAY: block; MARGIN: 0px auto 10px; WIDTH: 403px; CURSOR: hand; HEIGHT: 53px; TEXT-ALIGN: center" alt="" src="http://1.bp.blogspot.com/_Xlazsp1mHx0/TDTKfThtBYI/AAAAAAAAAKc/ilvA5lrc1qQ/s320/A%2520Neg%2520and%2520B%2520Neg%2520Special%2520Need%2520Web%2520Banner.jpg" border="0" /></a><br /><div><strong></strong></div><br /><div><strong>What Is a Platelet Donation?</strong><br /><br />During a platelet donation, a small portion of your blood (less than one pint at a time), is drawn from your arm and passed through a sophisticated cell-separating machine. The machine collects the platelets and safely returns the remaining blood components, along with some saline, back to you. After the donation you can resume your normal activities, avoiding heavy lifting or strenuous exercise that day.<br /><br /><strong>Should You Be a Platelet Donor?</strong></div><br /><div><strong></strong></div><br /><div>A single platelet donation can provide enough platelets for a full therapeutic dose for a patient in need. In fact, some platelet donations yield enough platelets for two or three therapeutic doses. By contrast, it takes about five whole blood donations to produce a single therapeutic dose. Many patients who need platelets are undergoing chemotherapy or organ transplant and have weakened immune systems. A platelet dose from a single donor reduces the patient’s exposure to multiple donors and is therefore preferred by many physicians. Check out this <a href="http://www.redcrossblood.org/apheresis-warriors" jquery1278527356694="22">video</a>.</div><br /><div></div><br /><div><strong>Key Facts</strong></div><br /><ul><br /><li>Donors should not take any aspirin or products containing aspirin 48 hours before donation</li><br /><li>You can donate up to 24 times per year. </li><br /><li>The donation takes approximately 1 1/2 to 2 1/2 hours.</li><br /><li>Call 1-800-RED-CROSS for platelet donation opportunities near you. </li><br /><li>Donors have the option to watch a movie, listen to music or simply relax during the donation process. </li><br /><li>A platelet donation is also called a ‘platelet apheresis’ or ‘platelet pheresis’ donation. </li><br /><li>If you are a platelet donor, you can still make regular whole blood donations. Both gifts are vitally important to patients with life threatening diseases. </li></ul>Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-52006655885198983222010-03-22T21:29:00.001-04:002010-03-22T21:31:13.546-04:00Ideas for Sickle Cell Rochester 2010Planet a Fruit Tree or have Fruit and vegetable project. Go apple<br />picking or some kind of fruit picking experience for the kids. (Tracy)<br />Have a walk to raise money for Back to School supplies 4 kids (Tiffany)<br />See Breeze trip for 20 kids at a cost of $20 per kid w/ picnic for<br />total cost of $400 (Ronald)<br />Do awareness w/ school by expert or parent. The who is a TBD (Tiffany).<br />Parent Education and Advocacy Event (Ronald and Tiffany)<br />Trip to the Science Museum, Strong Museum of Play, Rochester, Buffalo,<br />Syracuse Zoo or Cultural event (Ronald)<br />Social Group for Parents = day or evening off from the kids Sickle<br />Cell “SC Café” (Tiffany)<br />Social Group for older Kids = day or evening away from the parents (Tiffany)<br />Have 1 to 2 parents attended the national event for 2010 (Ronald)<br /><br />Support campaign to reissue the SC postage stamp for the 160th<br />anniversary on the Discovery of Sickle Cell Disease (Ronald)Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-21329646896647353832010-01-31T13:41:00.002-05:002010-01-31T13:50:04.094-05:00Transitional care for young adults moving into the adult health care system<a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="http://2.bp.blogspot.com/_Xlazsp1mHx0/S2XQy3IDjjI/AAAAAAAAAIk/wRP4NWWvUFg/s1600-h/Tiffany_Pulcino_MD.jpg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 169px; height: 252px;" src="http://2.bp.blogspot.com/_Xlazsp1mHx0/S2XQy3IDjjI/AAAAAAAAAIk/wRP4NWWvUFg/s320/Tiffany_Pulcino_MD.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5432978097702145586" /></a><br />Tiffany Pulcino, M.D. <br />Dr. Pulcino was born and raised in Rochester. She attended Mount Sinai Medical School where she completed both her medical degree and master's degree in public health with honors in research. She completed her residency in Internal Medicine and Pediatrics at the University of Rochester in 2008.<br />Dr. Pulcino is an Instructor of Internal Medicine and Pediatrics at the University of Rochester. She is board eligible in both Internal Medicine and Pediatrics. She is a member of the American College of Physicians and the American Academy of Pediatrics.<br />Dr. Pulcino's special interest is transitional care: the process of young adults moving into the adult health care system, especially those with medical problems diagnosed in childhood, such as cystic fibrosis, sickle cell anemia, inflammatory bowel disease, and congenital heart disease. <br />"My goal is to form a trusting partnership with my patients and their families. Together, we can formulate health goals based on their individual needs and the most recent medical evidence." When not working, Dr. Pulcino enjoys spending time with her husband and son, kayaking, and hiking. <br />Contact<br />Culver Medical Group<br />913 Culver Road<br />Rochester, NY 14609<br />Administrative: 585 654-5432 <br />Fax: 585 288-7871Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-12671874535699681852009-12-11T10:52:00.001-05:002009-12-11T10:53:16.637-05:00"Mini" Transplant May Reverse Severe Sickle Cell Disease"Mini" Transplant May Reverse Severe Sickle Cell Disease<br />Main Category: Blood / Hematology<br />Also Included In: Transplants / Organ Donations; Stem Cell Research; Clinical Trials / Drug Trials<br />Article Date: 10 Dec 2009 - 3:00 PST<br /><br /> email to a friend printer friendly view / write opinions rate article<br />Current Article Ratings: <br /><br />Patient / Public: <br /> <br />Health Professional: 4.5 (2 votes)<br /> <br />Article Opinions: 0 posts <br /><br />Results of a preliminary study by scientists at the National Institutes of Health and Johns Hopkins show that "mini" stem cell transplantation may safely reverse severe sickle cell disease in adults.<br /><br />The phase I/II study to establish safety of the procedure, published December 10 in the New England Journal of Medicine, describes 10 patients with severe sickle cell disease who received intravenous transplants of blood-forming stem cells. The transplanted stem cells came from the peripheral blood of healthy related donors matched to the patients' tissue types.<br /><br />Using this procedure, nine of 10 patients treated have normal red blood cells and reversal of organ damage caused by the disease.<br /><br />Jonathan Powell, M.D., Ph.D., associate professor at the Johns Hopkins Kimmel Cancer Center, says the intravenous transplant approach for sickle cell disease, caused by a single mutation in the hemoglobin gene, does not replace the defective gene, but transplants blood stem cells that carry the normal gene.<br /><br />Sickle cell disease, named for the "deflated" sickle-shaped appearance of red blood cells in those with the disease, hinders the cells' ability to carry oxygen throughout the body. In severe cases, it causes stroke, severe pain, and damage to multiple organs, including the lungs, kidneys and liver.<br /><br />All patients in the study, ranging in age from 16 to 45, were treated at the NIH with what researchers call a non-myeloablative or "mini" transplant, along with an immune-suppressing drug called rapamycin.<br /><br />Conventional transplant methods use high doses of chemotherapy to wipe out the immune system before the transplanted cells are injected, a process that has many side effects, including serious bacterial and fungal infections, which may kill some patients. In mini-transplants, lower doses of medication and radiation are used to make room for the donor's cells, the new source for healthy red blood cells in the patient.<br /><br />According to Powell, side effects, including low white blood cell counts, were few and very mild compared with conventional bone marrow transplantation. But in nine of the 10, donor cells now coexist with the patients' own cells. One patient was not able to maintain the transplanted cells long term.<br /><br />Minitransplants for sickle cell disease were tested in patients almost a decade ago, but were unsuccessful because the patients' immune systems rejected the transplanted cells, according to Powell, but by employing the drug rapamcyin, he says this new approach promotes the coexistence of the host and donor cells.<br /><br />Powell's earlier research in mice showed that rapamycin inhibits an enzymatic pathway that suppresses the immune system and makes the host and donor cells tolerant to each other.<br /><br />The NIH/Johns Hopkins team is conducting further studies on immune cells gathered from patients in their study, and looking at a combination of rapamycin with a well-known cancer drug called cyclophosphamide.<br /><br />Other teams at Johns Hopkins are studying the use of half-matched donors for transplants in sickle cell patients, helping to widen the pool of potential donors for stem cell transplantation.<br /><br />Funding for the study was provided by the National Institute of Diabetes, Digestive, and Kidney Diseases and the National Heart, Lung and Blood Institute at the NIH.<br /><br />Study authors at the NIH include principal investigator John Tisdale, as well as Matthew Hsieh, Elizabeth Kang, Courtney Fitzhugh, M. Beth Link, Roger Kurlander, Richard Childs, and Griffin Rodgers.<br /><br />Source: Johns Hopkins MedicineMarketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-20752687499477278302009-12-11T10:52:00.000-05:002009-12-11T10:52:02.874-05:00"Mini" Transplant May Reverse Severe Sickle Cell Disease<a href="http://www.medicalnewstoday.com/articles/173526.php">"Mini" Transplant May Reverse Severe Sickle Cell Disease</a>Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-70943962124137985872009-05-18T17:09:00.001-04:002009-05-18T17:10:45.043-04:00Additional Links I found todayhttp://www.blackplanet.com/Sickle-Cell/<br /><br />http://www.sicklecellart.com<br /><br />http://www.sicklecellstamps.com/Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-59547054840526289942008-10-22T12:57:00.001-04:002008-10-22T13:00:06.235-04:00Link to Sickle Cell News release on www.marrow.org<p>Good Morning Friends,</p><p>Hope you are all well today. Below is a link with some very exciting news. Thanks to all of you and your continued support and efforts to “Save a Life” now even more people will receive a transplant.It is truly an honor to work with all of you.</p><p>Sue</p><p>Here is the link to the news release we sent out this week regarding the new sickle cell clinical trial. <a href="http://www.marrow.org/NEWS/News_Releases/2008/Sickle_Cell_Study.html">http://www.marrow.org/NEWS/News_Releases/2008/Sickle_Cell_Study.html</a></p>Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-20764832342257072682008-09-24T16:12:00.001-04:002008-09-24T16:12:59.937-04:00Xerox Corp Community Involvement Cooley’s Anemia Foundation of Monroe CountyCooley’s Anemia Foundation of Monroe County<br />Cooley's Anemia is a blood disorder. Our group raises funds to pay for medical treatment for those in need but can not afford the services. A percentage of the funds raised also goes to research for a Cure for Cooley’s as well as sickle cell and other blood disorders.<br />Volunteers are needed to help in fund-raisers and to staff the Bingo program for 1 hour per month or more if you are able.<br />EMPIRE BINGO HALL AT 380 EMPIRE BOULEVARD<br /><br /><a href="http://www.thalassemia.org/sections.php?sec=3&cooleys_sess=3c3f7dc7aefcf2d3de7e37f2954b7d29">http://www.thalassemia.org/sections.php?sec=3&cooleys_sess=3c3f7dc7aefcf2d3de7e37f2954b7d29</a><br />Shirley Cammilleri585-482-5587<br />Immediate and ongoing needMarketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-45053402299307085652008-08-06T16:29:00.000-04:002008-08-06T16:43:55.871-04:00Stopped by to drop off a logo<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiFlnWvx_GYq7aTaelVYXZPtfljLIEulXvraHpb-b-sIJfB4TfIAecYcyqVJ-3c64xMiB7R3cUYc1-m5wLqycMFRIJKSMikcQH3OHtlZZd9EGfCygGnHw5t4PPLx40cvFfv_5-32wl4fTw/s1600-h/image002.jpg"><img id="BLOGGER_PHOTO_ID_5231508124063408674" style="CURSOR: hand" alt="" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiFlnWvx_GYq7aTaelVYXZPtfljLIEulXvraHpb-b-sIJfB4TfIAecYcyqVJ-3c64xMiB7R3cUYc1-m5wLqycMFRIJKSMikcQH3OHtlZZd9EGfCygGnHw5t4PPLx40cvFfv_5-32wl4fTw/s320/image002.jpg" border="0" /></a><br /><div></div>Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-22741336858200469202008-07-30T13:24:00.000-04:002008-07-30T13:25:44.457-04:00Defining the mission statementThese questions are used to define the SC Group to have a good start in our communication<br /><br />What is your vision (what do you want to be doing) for the SC Group?<br />- End of 2008 (short term)<br />- End of 2009 (long term)<br />- End of 2012 (future)<br />What are your goals(what do you want o accomplish) for the SC group?<br /><br />The answers to these questions will form the mission statement that you can articulate and share with others<br />I will conduct research on SC and so will you. Your goal is to learn new information we can share. I will also do a situational (SWOT) Analysis on SC in general<br /><br />Identify the people, audience you want to reach. <br />- For me it would be the government<br />- Educate family to become ambassador for the cause<br />- Educate friends to become ambassadors for the causeMarketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-44282183342037049332008-07-28T14:10:00.002-04:002008-07-28T14:13:21.361-04:00Closing out on another Month JulyTiffany has started meetings with the doctors and nursing staff at Strong hospital to kick off the Sickle Cell supoort group. The first meeting went well and the next is in mid August.Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0tag:blogger.com,1999:blog-5059039568754833581.post-65980238048705145092008-07-14T10:46:00.000-04:002008-07-14T10:49:35.880-04:00Happy Monday everyone. There will be a meeting next Monday July 21 discussing a Sickle Cell support group with <span class="blsp-spelling-corrected" id="SPELLING_ERROR_0">participants</span> from the local community and Strong Hospital.Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com3tag:blogger.com,1999:blog-5059039568754833581.post-74678614011170189062008-07-11T15:26:00.000-04:002008-07-14T10:49:35.881-04:00Internet marketing and New Media MKT570<div>This blog was created because of an assignment for a class I am taking in Internet marketing and New Media for a Masters of Science with a consentration in Marketing from Roberst Wesleyan College in upstate New York. I guess I'm doing well so far. I have 2 kids with Sickle Cell and I figure this may be a topic I could discuss and share.</div>
<br /><div> </div>
<br /><div> </div>Marketing_Guruhttp://www.blogger.com/profile/08152918374248983449noreply@blogger.com0